Myasthenia gravis and innovative therapies: a study provides a critical overview of the data in the literature

Partager sur

Italian researchers have compiled recent data from the literature on the efficacy of new treatments for myasthenia gravis, in particular complement inhibitors and fetal immunoglobulin receptor (FcRn) blockers.

  • A Cochrane-type approach was used, resulting in a simple meta-analysis and a network meta-analysis,
  • The observation windows for product efficacy were significantly different (26 weeks for eculizumab and ravulizimab, 28 days for efgartigimod, 43 days for rozanolixitumab, 12 weeks for zilucoplan and up to 52 weeks for rituximab),
  • The authors confirm a better therapeutic benefit for complement inhibitors and FcRn compared with rituximab.
  • The network meta-analysis argues in favour of efgartigimod in particular.

 

Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis. Saccà F,  Pane C,  Ezequiel Espinosa P et al. Eur J Neurol. 2023 May 19. doi: 10.1111/ene.15872. Epub ahead of print. PMID: 37204031

On the same topic